Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Lamassu Pharma is raising $2,903,156.00 in new funding. Sources indicate as part of senior management President, Gabi Hanna played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lamassu Pharma

Lamassu Pharma was formed to fill a significant gap in the drug development process from post discovery and animal efficacy models to clinical phase. We are capitalizing on our expertise in early translational research to bring products to phase I/II clinical trial. Our first drug RABI767 is a novel small molecule therapy for acute pancreatitis. This was developed at Mayo Clinic by leading scientists, and has profound efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis in animal models. Acute pancreatitis is a leading cause of emergency department visits and gastrointestinal admissions in the United States with over 330,000 hospital admissions per year in US with significant mortality and long term complications. Our ultimate goal is saving the lives of patients afflicted with this disease, and improving the quality of life for the survivors.

To learn more about Lamassu Pharma, visit http://www.lamassupharma.com/

Contact:
Gabi Hanna, President
919-667-8571
https://www.linkedin.com/in/gabi-hanna-md-b3953748/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved